Jim Simons Inozyme Pharma, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 164,800 shares of INZY stock, worth $585,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,800

Previous 187,839 12.27%

Holding current value

$585,040

Previous $837,000 2.87%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.31 - $6.0 $99,298 - $138,234	-23,039 Reduced 12.27%	164,800 $861,000
Q2 2024 Aug 09, 2024	BUY	$4.33 - $7.31 $61,221 - $103,356	14,139 Added 8.14%	187,839 $837,000
Q1 2024 May 13, 2024	SELL	$4.14 - $7.66 $185,472 - $343,168	-44,800 Reduced 20.5%	173,700 $1.33 Million
Q4 2023 Feb 13, 2024	SELL	$2.71 - $4.5 $208,962 - $346,986	-77,108 Reduced 26.08%	218,500 $931,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $230,708 - $394,856	56,408 Added 23.58%	295,608 $1.24 Million
Q2 2023 Aug 11, 2023	BUY	$4.93 - $6.74 $261,782 - $357,894	53,100 Added 28.53%	239,200 $1.33 Million
Q1 2023 May 12, 2023	SELL	$1.3 - $5.73 $94,640 - $417,144	-72,800 Reduced 28.12%	186,100 $1.07 Million
Q4 2022 Feb 13, 2023	BUY	$1.05 - $2.82 $108,675 - $291,870	103,500 Added 66.6%	258,900 $272,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $5.45 $95,347 - $202,195	37,100 Added 31.36%	155,400 $416,000
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.96 $340,480 - $634,144	106,400 Added 894.12%	118,300 $564,000
Q1 2022 May 13, 2022	BUY	$3.87 - $7.55 $46,053 - $89,845	11,900 New	11,900 $49,000

Others Institutions Holding INZY

# of Institutions

Shares Held

52.7M

Call Options Held

17.6K

Put Options Held

2.7K

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $143M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account